WIN 68210

Drug Profile

WIN 68210

Alternative Names: SW 68210

Latest Information Update: 06 Aug 2002

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Developer Nonindustrial sources; Sanofi-Synthelabo
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 30 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
  • 02 Jun 1999 New profile
  • 02 Jun 1999 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top